Mystery investors back a new NASH approach; GSK antibiotics sale triggers layoff fears
A mystery investor is backing a new late-stage effort to treat NASH, leading an $80 million crossover round for Sagimet Biosciences.
The Series F round …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
